MARKET

AGLE

AGLE

Aeglea Bio
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.59
-0.01
-0.15%
Closed 16:00 06/14 EDT
OPEN
6.66
PREV CLOSE
6.60
HIGH
6.68
LOW
6.50
VOLUME
88.99K
TURNOVER
--
52 WEEK HIGH
11.38
52 WEEK LOW
6.36
MARKET CAP
323.07M
P/E (TTM)
-4.6572
1D
5D
1M
3M
1Y
5Y
The Daily Biotech Pulse: FDA Nod For Novartis, iRhythm CEO Quits Abruptly, Moderna Inks Vaccine Supply Agreements
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 1)
Benzinga · 06/02 12:20
Stocks That Hit 52-Week Lows On Tuesday
    Before 10 a.m. ET on Tuesday, 4 companies set new 52-week lows.
Benzinga · 06/01 14:13
BRIEF-Aeglea Bio Therapeutics Inc Files For Stock Shelf Of Up To 19.0 Million Shares Of Common Stock By Selling Stockholder
reuters.com · 05/28 22:25
JonesTrading Sticks to Their Buy Rating for Aeglea Biotherapeutics (AGLE)
JonesTrading analyst Soumit Roy reiterated a Buy rating on Aeglea Biotherapeutics (AGLE) today and set a price target of $22.00. The company's shares
SmarterAnalyst · 05/10 17:05
Needham Remains a Buy on Aeglea Biotherapeutics (AGLE)
In a report released today, Chad Messer from Needham reiterated a Buy rating on Aeglea Biotherapeutics (AGLE), with a price target of $12.00. The
SmarterAnalyst · 05/10 16:55
8-K: Aeglea BioTherapeutics, Inc.
Edgar Online - (EDK = 8-Ks/S1/S-4) · 05/10 13:14
Aeglea BioTherapeutics EPS misses by $0.14
Aeglea BioTherapeutics (AGLE): Q1 GAAP EPS of -$0.28 misses by $0.14.Cash, cash equivalents, marketable securities and restricted cash of $128.5M. Based on Aeglea's current operating plan, management believes it has
Seekingalpha · 05/10 12:47
10-Q: AEGLEA BIOTHERAPEUTICS, INC.
Edgar Online - (EDG = 10Q, 10K) · 05/10 12:40
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AGLE. Analyze the recent business situations of Aeglea Bio through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AGLE stock price target is 15.86 with a high estimate of 26.00 and a low estimate of 9.00.
EPS
Institutional Holdings
Institutions: 118
Institutional Holdings: 43.09M
% Owned: 87.89%
Shares Outstanding: 49.02M
TypeInstitutionsShares
Increased
22
2.20M
New
4
604.70K
Decreased
33
2.52M
Sold Out
11
170.03K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.10%
Pharmaceuticals & Medical Research
+0.13%
Key Executives
Non-Executive Chairman/Independent Director
Russell Cox
President/Chief Executive Officer/Director
Anthony Quinn
Chief Operating Officer
Leslie Sloan
Vice President/Controller
Steven Weber
Other
Michael Hanley
Independent Director
Sara Brownstein
Independent Director
V. Bryan Lawlis
Independent Director
Alison Lawton
Independent Director
Ivana Magovcevic-Liebisch
Director
Bryan Lawlis
Independent Director
Sandesh Mahatme
Independent Director
Armen Shanafelt
No Data
  • All
  • Financials
  • Insiders
More
About AGLE
Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing a human enzyme therapeutics as advanced solutions for rare and other high-burden diseases. The Company’s product candidates are Pegzilarginase, ACN00177 and AEB5100. Its Pegzilarginase is a recombinant human Arginase one that enzymatically degrades the amino acid arginine to lower arginine levels in patients with Arginase One Deficiency. Its engineered pegzilarginase with modifications that enhance the stability and arginine-degrading activity of the enzyme in human plasma. The Company is evaluating Pegzilarginase in a global pivotal Phase III PEACE (Pegzilarginase Effect on Arginase one Deficiency Clinical Endpoints) trial and in a Phase II open-label extension study for patients with Arginase One Deficiency. Its ACN00177 is a PEGylated or polyethylene glycol modified, human enzyme engineered to degrade free homocysteine and homocystine in patients with Homocystinuria.

Webull offers kinds of Aeglea Bio Therapeutics Inc stock information, including NASDAQ:AGLE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AGLE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AGLE stock methods without spending real money on the virtual paper trading platform.